Peptide Impurity Profiling: Genotoxic Impurities (ICH M7), Identification Threshold, and CMC Strategy 2026

Industry Authority | 2026-07-10 | 13 min read

A 2026 industry guide to peptide impurity profiling: ICH M7 genotoxic impurity thresholds, identification thresholds for non-genotoxic impurities, peptide-specific impurities (truncation, deletion, oxidation), and CMC strategy.

Introduction: why impurity profiling matters

Peptide drug impurities affect safety, efficacy, and regulatory approval. Unlike small molecules, peptides have well-defined impurity profiles tied to the synthesis process. But the complexity is higher: a 30-amino acid peptide can have 30+ possible truncation products, dozens of deletion sequences, and various degradation products.

Regulatory agencies (FDA, EMA, PMDA) require comprehensive impurity characterization for any peptide drug substance or drug product. This 2026 guide covers:

ICH M7 genotoxic impurity thresholds
ICH Q3A identification and qualification thresholds
Peptide-specific impurities
Analytical strategies for impurity profiling
CMC documentation requirements

ICH M7: genotoxic impurity control

Background

ICH M7 (Mutagenic Impurities) classifies impurities by mutagenic and carcinogenic potential and sets acceptable intake limits.

Threshold of Toxicological Concern (TTC)

The TTC concept: any impurity with unknown carcinogenicity that is consumed at <1.5 µg/day over a lifetime is considered to pose negligible cancer risk. This is the default acceptable intake for any unclassified impurity.

For peptide drugs:

Most peptides have low molecular weight but high molecular complexity. Daily doses vary:

Semaglutide: 0.25 - 2.4 mg weekly → ~0.04 - 0.35 mg/day
Tirzepatide: 2.5 - 15 mg weekly → ~0.35 - 2.1 mg/day
BPC-157: research dose varies (typically 250 - 500 µg/day)
Liraglutide: 1.8 mg/day

For these doses, the TTC of 1.5 µg/day corresponds to:

0.15% w/w for a 1 mg/day dose
0.075% w/w for a 2 mg/day dose

Class-specific limits:

Some impurities are more potent carcinogens and have lower acceptable intakes:

N-nitrosamines: 18 ng/day (after 2020 nitrosamine crisis)
Aflatoxin-like compounds: <1 µg/day
Alkylating agents (mustards, epoxides): variable

Control strategy for peptide genotoxic impurities:

**Risk assessment**: Identify all potential genotoxic impurities from synthesis
**Analytical method development**: Sensitive methods (LOQ << TTC) for each impurity
**Process control**: Purge studies showing impurity removal during synthesis
**Specification**: Set specification well below TTC
**Batch release testing**: Confirm impurities below specification

ICH Q3A: identification and qualification thresholds

Identification threshold:

The threshold above which an impurity must be identified:

| Maximum Daily Dose | Identification Threshold | | --- | --- | | ≤2 g/day | 0.10% | | >2 g/day | 0.05% |

For peptide drugs (typical dose <100 mg), the threshold is 0.10% of the drug substance.

Qualification threshold:

The threshold above which an impurity must be qualified for safety (toxicology testing):

| Maximum Daily Dose | Qualification Threshold | | --- | --- | | ≤2 g/day | 0.15% | | >2 g/day | 0.05% |

Qualification requires toxicology studies demonstrating safety at the levels observed in the drug substance.

Reporting threshold:

The threshold above which an impurity must be reported in the CMC documentation:

| Maximum Daily Dose | Reporting Threshold | | --- | --- | | ≤2 g/day | 0.05% | | >2 g/day | 0.03% |

For peptide drugs, this is 0.05%.

Peptide-specific impurities

Truncation products

Truncation products are the most common peptide impurities, formed when SPPS coupling fails at one or more positions:

N-terminal truncation (missing 1-3 amino acids)
C-terminal truncation (rare in SPPS but possible)
Internal truncation

Truncation products are typically:

Easily detected by HPLC (different retention time)
Characterized by MS (lower mass than target)
Generally safe (similar to partial sequences)
Sometimes pharmacologically active (concern for biologics)

Deletion sequences

Deletion sequences are missing one amino acid within the chain (not at the terminus):

Formed by incomplete coupling of an internal amino acid
Detected by MS (mass difference of one amino acid)
May be immunogenic (new T-cell epitopes exposed)
Quantification requires HPLC with good resolution

Oxidation products

Sensitive residues:

Methionine (sulfoxide formation, +16 Da)
Cysteine (disulfide formation, +2 Da per Cys)
Tryptophan (oxindole formation, +4 to +32 Da)
Histidine (variable oxidation)

Oxidation is prevented by:

Low-temperature processing
Antioxidants in buffers
Nitrogen overlay during storage
pH control (avoid alkaline conditions)

Deamidation products

Asparagine and glutamine deamidate to aspartate and glutamate:

Asn → Asp/isoAsp (+1 Da)
Gln → Glu (+1 Da)

Deamidation rates depend on:

Sequence context (Asn-Pro, Asn-Gly are fastest)
pH (maximal at pH 7-8)
Temperature
Buffer composition

Racemization

During SPPS, amino acids can racemize (L → D):

Detected by chiral amino acid analysis
Detected by HPLC (different retention of D-peptide)
Concerning for immunogenicity
Most common with Cys, His, Asp, Ser

Aggregates

Peptide aggregation is a major concern:

Dimers, trimers, higher-order aggregates
Detected by size-exclusion chromatography
Detected by analytical ultracentrifugation
Can be immunogenic
Can be reduced by formulation optimization

Analytical strategies

HPLC method development

For peptide impurity profiling, the HPLC method must:

Separate all impurities from the main peak
Have sensitivity to 0.05% level
Be stability-indicating (degradation products detectable)
Be reproducible across batches

Typical conditions:

Column: C18 or C8, 4.6 x 150 mm, 3 µm
Mobile phase: acetonitrile/water with 0.1% TFA
Gradient: 5-95% acetonitrile over 30 minutes
Detection: 220 nm (peptide bond) and 280 nm (aromatic residues)
Flow rate: 1 mL/min
Column temperature: 30-40°C

LC-MS for impurity identification

LC-MS is essential for impurity identification:

ESI-MS or APCI-MS for molecular weight
MS/MS for sequence confirmation
Accurate mass (FT-MS, Q-TOF) for unambiguous identification
Quantification by UV (220 nm) with response factors

Peptide mapping

Peptide mapping (digestion with trypsin or other protease followed by LC-MS/MS) provides:

Confirmation of amino acid sequence
Identification of modifications (oxidation, deamidation)
Comparison of batch-to-batch consistency
Stability-indicating capability

Other analytical methods

Amino acid analysis (AAA): quantitative amino acid composition
Chiral amino acid analysis: detect racemization
Capillary electrophoresis: orthogonal to HPLC
Size-exclusion chromatography (SEC): aggregates
Dynamic light scattering (DLS): subvisible aggregates
Circular dichroism (CD): secondary structure
NMR: structural characterization

CMC documentation requirements

Drug substance CMC:

Description of manufacturing process (including all reagents, solvents, and conditions)
Identification of all impurities based on process knowledge
Specification with acceptance criteria for each impurity
Analytical methods with validation
Batch analysis data (typically 3-5 batches)
Stability data (long-term and accelerated)

Drug product CMC:

Impurities formed during formulation (degradation products)
Process-related impurities carried into drug product
Specification for total impurities and individual impurities
Stability-indicating method
Justification of impurity specifications based on safety

Regulatory submissions:

For an IND or IMPD, the CMC section must include:

Comprehensive impurity listing
Structural characterization of impurities above identification threshold
Toxicity qualification for impurities above qualification threshold
Justification of specification limits
Analytical method validation
Process control to limit impurities

Risk assessment and lifecycle management

Initial risk assessment (development phase):

Identify all potential impurities from synthesis
Predict impurity levels based on similar peptides
Set initial specifications based on predicted levels
Develop analytical methods

Lifecycle management (post-approval):

Monitor impurities in commercial batches
Investigate any OOS results
Update specifications based on manufacturing experience
Implement process improvements to reduce impurities
Manage CMC variations per regulatory requirements

Summary

Peptide impurity profiling is a critical regulatory and quality activity. Modern analytical methods (LC-MS, peptide mapping, chiral analysis) enable comprehensive characterization. CMC strategy must include:

ICH M7 risk assessment for genotoxic impurities
Identification and qualification of all impurities >0.10%
Specification based on safety and process capability
Stability-indicating analytical methods
Lifecycle management of impurity control

For research and pharmaceutical-grade peptide manufacturing, robust impurity profiling is not optional — it's the foundation for regulatory approval and patient safety.

ZePeptide content is for lawful laboratory and in-vitro research sourcing. Products are not supplied for human or veterinary use.

Research peptide catalog Supplier checklist More peptide guides